January 21, 2003

Medical Applications – And Opportunities – Being Realized in Nanotechnology and MEMS Technology, According to Report by MedMarket Diligence

FOOTHILL RANCH, CA — The recent past of nanotechnology has been characterized by an abundance of promise and a scarcity of realistic assessment. However, what was recently only pure science is now becoming – and in a growing number of cases has already become – commercial reality. There are numerous examples:  Micro-electro-mechanical systems (MEMS) devices can inoculate individual red blood cells as they travel through a capillary. Nanoparticles can be directed to specific tissues or cells; they can enter individual cells to seek specific molecules, report on their presence, and be activated to initiate a treatment procedure. These developments and many like them are no longer in the realm of science fiction — many are now in clinical trials.

“Hundreds of commercial and research groups are developing technologies that work at the molecular and cellular levels, and the synergistic integration of MEMS, microfluidics, gene chips, LOC, and nanomedicine is leading to new applications and markets,” says Patrick Driscoll, President of MedMarket Diligence. These advances are now proving their potential in delivering individually specific, minimally invasive, and less expensive medicine, according to Driscoll.

The MedMarket Diligence report, “Current Medical Technologies, Applications & Market Opportunities in Nanotechnology & MEMS, 2002-2012 (publishing January 2003) reveals the advanced state of commercial development for MEMS- and nanotechnology-based drug delivery, surgery aids, orthopedic implants, endoscopic microscopes and many others. The report details the status, outlook and opportunities in the commercial development, with profiles of over 80 companies intensely engaged in this field.  For more detail on the report, see http://www.mediligence.com/rpt-t601.htm.

MedMarket Diligence also publishes “MedMarkets”, a monthly publication that analyzes the market implications of new medical technology. MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries.  For more information on medical technology market analysis from MedMarket Diligence, contact Patrick Driscoll at (949) 859-3401, email, or visit the website at http://www.mediligence.com to view a sample issue of “MedMarkets”.

Contact: Patrick Driscoll, (949) 859-3401.